巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Sesen Bio

    SESN
    0.394
    0.010
    3.49%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Sesen Bio - 延遲價格・最後更新於 28/09 8:28
    最高位
    0.399
    最低位
    0.385
    開市價
    --
    前收市價
    0.381
    成交量(千)
    9.69
    成交額(百萬)
    0.04
    買入
    0.323
    賣出
    0.463
    每手股數
    --
    市值(百萬)
    78.59
    市盈率
    1.200
    息率
    --
    差價
    --
    52週高低
    1.470 - 0.365
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Sesen Bio
    證券代碼
    SESN.US
    所屬板塊
    Biotechnology
    公司業務
    Sesen Bio Inc is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The company's product candidate, Vicineum, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. The company plans to conduct an additional Phase 3 clinical trial for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG in connection with the potential resubmission of a BLA.
    發行量
    199463645
    公司總部
    245 First Street, Suite 1800
    公司網址
    https://www.sesenbio.com
    公司電郵
    ir@sesenbio.com
    公司電話
    +1 617 444-8550
    暫無內容

    關於

    Sesen Bio(SESN.US)所屬的行業板塊為Biotechnology。
    Sesen Bio Inc is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The company's product candidate, Vicineum, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. The company plans to conduct an additional Phase 3 clinical trial for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG in connection with the potential resubmission of a BLA.
    詳細公司背景可參考: https://www.sesenbio.com